MX9702789A - Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos. - Google Patents

Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.

Info

Publication number
MX9702789A
MX9702789A MX9702789A MX9702789A MX9702789A MX 9702789 A MX9702789 A MX 9702789A MX 9702789 A MX9702789 A MX 9702789A MX 9702789 A MX9702789 A MX 9702789A MX 9702789 A MX9702789 A MX 9702789A
Authority
MX
Mexico
Prior art keywords
tnf
death domain
ligand
inhibitors
methods
Prior art date
Application number
MX9702789A
Other languages
English (en)
Inventor
Lih-Ling Lin
Andrea R Schivella
Jennifer Chen
James Graham
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/494,440 external-priority patent/US5849501A/en
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of MX9702789A publication Critical patent/MX9702789A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen novedosas proteínas ligandos del dominio de la muerte del receptor TNF ("TNF-R1-DD). También se describen polinucleotidos que codifican la proteína ligando del TNF-R1-DD, conjuntamente con vectores, células huésped y métodos para elaborar la proteína ligando del TNF-R1-DD. También se describen composiciones farmacéuticas que contienen la proteína ligando del TNF-R1-DD, métodos para el tratamiento de condiciones inflamatorias, y métodos para inhibir la union al dominio de al muerte del TNF-R. También se describen métodos para la identificacion de inhibidores de al union al dominio de la muerte del TNF-R así como los inhibidores identificados por dichos métodos.
MX9702789A 1994-10-19 1997-04-17 Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos. MX9702789A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32751494A 1994-10-19 1994-10-19
US08/494,440 US5849501A (en) 1994-10-19 1995-06-19 TNF receptor death domain ligand proteins and method to identify inhibitors of ligand binding
US08/533,901 US5852173A (en) 1994-10-19 1995-09-26 TNF receptor death ligand proteins and inhibitors of ligand binding

Publications (1)

Publication Number Publication Date
MX9702789A true MX9702789A (es) 1997-07-31

Family

ID=27406536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702789A MX9702789A (es) 1994-10-19 1997-04-17 Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.

Country Status (6)

Country Link
US (5) US5852173A (es)
EP (1) EP0787145A1 (es)
JP (1) JPH10507068A (es)
AU (1) AU698575B2 (es)
MX (1) MX9702789A (es)
WO (1) WO1996012735A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712381A (en) * 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US7108999B1 (en) 1994-12-15 2006-09-19 Yeda Research And Development Co. Ltd. Modulators of the function of FAS/AP01 receptors
US20020082401A1 (en) 1994-12-15 2002-06-27 Yeda Research And Development Company Modulators of the function of FAS/APO1 receptors
AU755662B2 (en) * 1995-02-22 2002-12-19 Yeda Research And Development Co. Ltd. Modulators of regulatory proteins
US6355780B1 (en) * 1995-02-22 2002-03-12 Yeda Research And Development Co. Ltd. Antibodies to the death domain motifs of regulatory proteins
US6762023B1 (en) 1998-11-30 2004-07-13 Drexel University Methods for identifying individuals at risk of developing osteoporosis
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
EP1414517A4 (en) * 2001-06-26 2008-02-06 Photomed Technologies Inc MULTIPLE WAVELENGTH ILLUMINATOR
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
WO2003011323A1 (en) * 2001-07-30 2003-02-13 Genset S.A. Agonists and antagonists of contabix for use in the treatment of metabolic disorders
MXPA05007019A (es) * 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
MX2009010946A (es) * 2007-04-11 2009-10-29 Alcon Res Ltd Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
KR20120091037A (ko) * 2009-10-01 2012-08-17 알콘 리서치, 리미티드 올로파타딘 조성물 및 그의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5296592A (en) * 1987-11-25 1994-03-22 Immunex Corporation Process for purifying interleukin-1 receptors
IL106271A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
AU642938B2 (en) * 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US5464938A (en) * 1990-04-09 1995-11-07 Immunex Corporation Isolated viral protein TNF antagonists
PT98805B (pt) * 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4)
CA2090705A1 (en) * 1990-08-28 1992-03-01 Michael C. Kiefer Genetic material encoding igfbp-5
WO1992014834A1 (en) * 1991-02-14 1992-09-03 The Whittier Institute For Diabetes And Endocrinology Insulin-like growth factor binding protein
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
AU671116B2 (en) * 1992-03-30 1996-08-15 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
ATE243712T1 (de) * 1992-11-04 2003-07-15 Chiron Corp Vekürztes insulinähnlichen wachstumsfaktor- bindendes protein mit mitogener aktivität
US5506340A (en) * 1994-04-01 1996-04-09 Centecor, Inc. Tumor necrosis factor inhibitors
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5741667A (en) * 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
EP1588712A1 (en) * 1995-02-22 2005-10-26 Yeda Research & Development Company, Ltd. Modulators of regulatory proteins
US5563039A (en) * 1995-03-31 1996-10-08 Tularik, Inc. TNF receptor-associated intracellular signaling proteins and methods of use
EP0822984A4 (en) * 1995-04-27 2000-05-03 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTORS IN MEN

Also Published As

Publication number Publication date
WO1996012735A1 (en) 1996-05-02
US20060188957A1 (en) 2006-08-24
JPH10507068A (ja) 1998-07-14
AU3826195A (en) 1996-05-15
AU698575B2 (en) 1998-11-05
US5843675A (en) 1998-12-01
US5852173A (en) 1998-12-22
EP0787145A1 (en) 1997-08-06
US20090092613A1 (en) 2009-04-09
US5948638A (en) 1999-09-07

Similar Documents

Publication Publication Date Title
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
EP1005540A4 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
DE69836956D1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
AU6238698A (en) Tumor necrosis factor receptor 5
DE69433552D1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
IL94039A0 (en) Antibodies to anti-cytotoxic proteins
PT662137E (pt) Transcricao de genes e radiacao ionizante: metodos e composicoes
BG112042A (bg) Човешки антитела, свързващи човешки тумор некрос фактор- ? (tnf-?)
DE69839340D1 (de) Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN
CA2158750A1 (en) Monoclonal antibodies to casein kinase i polypeptides
EP0590071A4 (en) Substantially pure receptor like tgf--g(b)1 binding molecules and uses thereof
NO20084906L (no) DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer
CA2296737A1 (en) Ligand for herpes simplex virus entry mediator and methods of use
ES2134336T3 (es) Activacion de proteina p53.
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
EP1005539A4 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
ATE171212T1 (de) Corticotropin freisetzende rezeptoren des faktor 2
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
DE69534471D1 (de) Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
WO2000067793A8 (en) Death domain containing receptor 4
CA2197233A1 (en) Methods of Identifying Compounds Useful for Treating Autoimmune Diseases
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: ADVANCED GLASSFIBER YARNS, LLC

MM Annulment or lapse due to non-payment of fees